Pancoast tumour and superior vena cava obstruction

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Pancoast syndrome and SVCO are anatomically linked thoracic presentations but are not interchangeable. A superior sulcus mass produces neuropathic and musculoskeletal symptoms by invading the thoracic inlet. SVCO reflects impaired venous return through the SVC, commonly from mediastinal tumour or nodes, but also from intraluminal thrombosis related to central venous devices or other benign causes.

The central decision in Pancoast disease is whether imaging and tissue staging identify a potentially curable, resectable superior sulcus cancer or advanced disease needing non-surgical control. The central decision in SVCO is whether airway or cerebral compromise demands immediate decompression before a full pathological work-up, or whether there is time to establish tissue diagnosis first.

Neither syndrome should be managed from a radiograph alone. Diagnostic planning should obtain the safest sample that will provide histology and molecular information without delaying rescue treatment. Functional status, patient goals, frailty and likely benefit must remain visible throughout the multidisciplinary discussion.

Key points

A Pancoast tumour is a superior sulcus lung cancer whose importance comes from local invasion of the lower brachial plexus, sympathetic chain, ribs, vertebrae or subclavian vessels rather than a distinctive histological type.
Severe shoulder or scapular pain radiating down the medial arm, C8-T1 weakness or wasting, and ipsilateral Horner syndrome should prompt deliberate inspection of the lung apex even without cough or haemoptysis.
A normal or equivocal chest radiograph does not exclude an apical lesion; contrast-enhanced CT and targeted MRI answer different staging questions.
Superior vena cava obstruction causes facial, neck and upper-limb oedema, venous distension, plethora, dyspnoea and symptoms worsened by bending or lying flat.
The urgency of SVCO is determined by airway, cerebral and haemodynamic compromise, not by the dramatic appearance of chest-wall collaterals alone.
Obtain histology before tumour-directed treatment whenever the patient is stable, because small-cell cancer, non-small-cell cancer, lymphoma, germ-cell tumour and benign thrombosis require different therapy.
Contrast CT of the chest maps the obstruction, collateral circulation, thrombus and safest biopsy target; venography is usually reserved for planned endovascular treatment.
Endovascular stenting can relieve severe malignant SVCO rapidly, while chemotherapy or radiotherapy is selected by cancer type, stage, performance status and current commissioning guidance.
Do not prescribe corticosteroid or anticoagulation reflexively: steroid may compromise lymphoma diagnosis, and anticoagulation needs a thrombotic indication with bleeding risk assessed.
Every treatment decision belongs in an acute oncology or lung-cancer pathway, with local emergency protocols taking precedence over textbook summaries.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Superior sulcus lung cancer

An apical primary lung tumour can invade lower brachial plexus, sympathetic chain, ribs and nearby vessels, producing the Pancoast syndrome.

Mediastinal malignancy

Lung cancer, lymphoma and metastatic nodes commonly compress or invade the superior vena cava, causing upper-body venous obstruction.

Intravascular thrombosis

Central venous catheters, pacing leads and malignancy-associated hypercoagulability can thrombose the superior vena cava without dominant external compression.

Non-malignant apical disease

Infection, inflammatory mass and rare benign tumours can mimic an apical cancer syndrome and require tissue-based distinction.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Apical local invasion
A superior sulcus mass extends through parietal pleura into chest wall and neurovascular structures rather than initially obstructing a major bronchus.
2
Neural disruption
Lower brachial-plexus involvement causes shoulder and ulnar-arm pain or hand weakness, while sympathetic-chain invasion produces Horner syndrome.
3
Central venous obstruction
Tumour or thrombus narrows the superior vena cava, raising venous pressure in the head, neck, upper limbs and chest wall.
4
Collateral flow and oedema
Collateral veins enlarge over time, but rapid obstruction causes facial swelling, airway oedema and impaired cerebral venous drainage before compensation develops.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Pancoast pain pattern

Persistent unilateral shoulder or scapular pain may precede respiratory symptoms. Radiation along the ulnar forearm, paraesthesia in the fourth and fifth fingers, grip weakness or intrinsic hand wasting suggests lower brachial plexus invasion rather than rotator-cuff disease.

Horner syndrome

Ipsilateral ptosis and miosis, sometimes with apparent enophthalmos or reduced facial sweating, indicate sympathetic-chain involvement. The pupil asymmetry is often clearer in dim light; absence of the complete triad does not exclude an apical tumour.

Neural or vertebral extensionRed flag

Progressive arm weakness, severe radicular pain, long-tract signs, gait disturbance, urinary symptoms or a sensory level suggest foraminal or spinal canal extension and require urgent MRI and spinal or oncology advice.

Typical SVCORed flag

Facial or neck swelling, bilateral arm swelling, dilated non-pulsatile neck or chest-wall veins, conjunctival suffusion, cough, dyspnoea, headache and a sensation of head fullness that worsens supine form the characteristic cluster.

High-grade SVCORed flag

Stridor, laryngeal oedema, severe orthopnoea, confusion, syncope, reduced consciousness, visual disturbance or haemodynamic instability indicate threatened airway, cerebral congestion or impaired venous return and justify immediate specialist rescue planning.

Thrombotic phenotypeRed flag

Abrupt symptoms, unilateral arm predominance, a tunnelled line, dialysis catheter, pacemaker lead or previous thrombosis increase the probability of an intraluminal component, although malignancy and thrombosis can coexist.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
ABCDE assessment with neurological and airway examinationFirst step
Why
Grade physiological threat before arranging definitive tests.
Interpretation and limitations
Document ability to speak and lie flat, respiratory effort, stridor, oxygenation, Glasgow Coma Scale, focal deficits, pupillary findings and arm perfusion. Deterioration overrides routine outpatient cancer pathways.
02
Contrast-enhanced CT chest and upper abdomen
Why
Define tumour anatomy, venous obstruction and possible metastatic disease.
Interpretation and limitations
For an apical lesion assess ribs, vertebral bodies, mediastinal nodes and vascular relationships. In SVCO identify the level and length of narrowing, collateral channels, extrinsic compression, intraluminal thrombus and a safe tissue target.
03
MRI thoracic inlet, brachial plexus and spine
Why
Map soft-tissue, neural and spinal extension accurately.
Interpretation and limitations
MRI is particularly useful for lower brachial plexus, neural foramina, spinal canal, vertebral marrow and subclavian-vessel relationships when considering radical treatment or explaining neurological signs.
04
Histology and molecular pathology
Why
Identify the malignancy and information needed for treatment selection.
Interpretation and limitations
Sample the safest high-yield site by image-guided core biopsy, bronchoscopy, EBUS or accessible node. Coordinate with pathology so lymphoma flow studies or lung-cancer molecular tests are not lost through an inadequate sample.
05
PET-CT and brain imaging
Why
Complete staging when radical therapy remains plausible.
Interpretation and limitations
PET-CT can reveal nodal or distant disease and a better biopsy site but inflammatory uptake is not specific. Brain MRI or CT follows tumour-specific staging guidance and neurological symptoms.
06
Baseline bloods and venous access review
Why
Prepare safely for contrast, biopsy and possible intervention.
Interpretation and limitations
Check full blood count, renal function, electrolytes, liver profile and coagulation as clinically indicated. Review anticoagulants and avoid placing non-essential cannulae in oedematous upper limbs when alternative access is available.
07
Duplex ultrasound or CT venography
Why
Clarify upper-limb or catheter-associated thrombosis when suspected.
Interpretation and limitations
Ultrasound can demonstrate accessible axillary or subclavian thrombus but cannot visualise all central veins. Cross-sectional venography and interventional review are needed when central clot affects stenting or anticoagulation decisions.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Cervical radiculopathy

Neck-related dermatomal pain and imaging of degenerative root compression can mimic brachial-plexus invasion but does not explain an apical mass or Horner syndrome.

Shoulder disease

Pain reproducible with joint movement and local musculoskeletal findings favours rotator-cuff or arthritic pathology over persistent neuropathic apical pain.

Mediastinal lymphoma

Bulky nodal disease, systemic symptoms and haematological tissue phenotype distinguish lymphoma-associated vena-caval obstruction from a lung primary.

Catheter-associated thrombosis

A device history, intraluminal thrombus and absence of a compressing mass support thrombotic superior vena cava obstruction.

Angio-oedema

Acute facial or tongue swelling without venous distension or chest-wall collaterals suggests allergic or bradykinin-mediated oedema rather than venous blockage.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01SVCO emergencyStabilise threatened airway or brainFirst stepStridor, rapidly progressive oedema, severe orthopnoea, confusion, syncope or reduced consciousness.

1Sit the patient upright, begin ABCDE monitoring, give oxygen for hypoxaemia and summon senior anaesthetic, acute oncology and interventional radiology help without delay.
2Use the fastest safe contrast imaging that will define obstruction and intervention, but do not force a severely orthopnoeic patient to lie flat without airway planning.
3Discuss urgent SVC stenting when rapid decompression is needed; arrange airway support and ensure any tension between biopsy and rescue treatment is resolved by the responsible specialists.
4After immediate danger is controlled, obtain or review tissue, evaluate thrombus and choose tumour-specific chemotherapy, radiotherapy or supportive care through the current MDT and local protocol.

02Stable SVCOSecure diagnosis before definitive treatmentDefinitiveVenous obstruction without airway, cerebral or haemodynamic compromise.

1Grade symptoms, elevate the head, review existing imaging and contact acute oncology the same day rather than starting undirected treatment.
2Obtain contrast CT and select the least hazardous biopsy route, preserving samples for lymphoma studies or lung-cancer biomarkers as the differential requires.
3EscalationAssess whether symptoms, clot burden and predicted tumour responsiveness favour stenting, anticoagulation, systemic therapy, radiotherapy or a combination; record the decision and escalation plan.
4Give clear return precautions for worsening breathlessness, voice change, swelling, headache, visual change, confusion or inability to lie flat.

03Pancoast stagingBuild a potentially radical pathwayAn apical lung mass with shoulder, neurological or sympathetic-chain features.

1Confirm local extent with contrast CT plus thoracic-inlet MRI, then secure adequate tissue by the safest route before assuming the mass is resectable lung cancer.
2Complete PET-CT, brain imaging, mediastinal nodal staging and cardiopulmonary fitness assessment according to the contemporary lung-cancer pathway.
3Discuss at a specialist thoracic oncology MDT with radiology, respiratory medicine, oncology and thoracic surgery; selected disease may receive induction chemoradiotherapy followed by en-bloc resection.
4If cure is not feasible, integrate radiotherapy or systemic treatment with neuropathic analgesia, rehabilitation and early palliative-care support.

04ThrombosisTreat a documented intraluminal componentImaging shows catheter-associated or cancer-associated SVC thrombosis.

1Assess bleeding, platelet count, renal function, drug interactions, catheter need and whether urgent mechanical decompression is also required.
2Start anticoagulation only under the current cancer-associated thrombosis or local vascular protocol, selecting agent and duration for cancer status, renal function and procedures.
3Coordinate catheter removal, thrombolysis or thrombectomy with haematology and interventional specialists; none is automatic solely because clot is visible.

Key medicines and prescribing safety4 treatments · regimens, roles and cautions

Correct hypoxaemia while urgent imaging and decompression are organised.

Controlled oxygen

Titrate to 94-98% saturation for most adults, or 88-92% if at risk of hypercapnic respiratory failure pending blood gases.

Oxygen does not relieve mechanical venous obstruction. Use a documented patient-specific target where present and repeat blood gases if hypercapnia is possible.

May reduce tumour-associated oedema in selected severe presentations or steroid-responsive disease.

Dexamethasone

Use only after senior acute-oncology advice at the dose in the current local oncological-emergency protocol.

Not routine for every SVCO. It can impair lymphoma tissue diagnosis and causes hyperglycaemia, infection risk, delirium and gastrointestinal adverse effects; do not delay definitive decompression.

Treat a confirmed or strongly suspected thrombotic component when benefits exceed bleeding risk.

Therapeutic anticoagulation

Choose and dose by the current cancer-associated thrombosis protocol, weight, renal function, platelet count and planned procedures.

Extrinsic tumour compression alone is not an indication. Check haemoptysis, brain metastases, thrombocytopenia, renal impairment and biopsy timing with haematology or oncology.

Relieve severe somatic and neuropathic pain from thoracic-inlet invasion.

Cancer-pain analgesia

Titrate non-opioid, opioid and neuropathic agents to effect using the local palliative formulary and regular reassessment.

Match the route to swallowing and renal function, prescribe bowel and nausea prophylaxis where appropriate, and avoid masking progressive neurological compromise without reassessment.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Airway compromise

Laryngeal and pharyngeal venous oedema can narrow the upper airway, particularly with rapidly progressive superior vena cava obstruction.

Cerebral oedema

Impaired cranial venous drainage may cause headache, confusion, reduced consciousness and other neurological deterioration, particularly when baseline cardiopulmonary reserve is limited.

Permanent neurological deficit

Continued brachial-plexus invasion causes weakness, muscle wasting, sensory loss and severe neuropathic pain, and potentially prolonging treatment and functional recovery.

Venous thrombosis and embolism

Stasis and cancer-related coagulation can extend thrombosis into upper-limb or central veins and occasionally embolise, and increasing the burden of otherwise local respiratory disease.

Local structural invasion

Tumour extension into ribs, vertebrae or spinal canal causes fracture, instability or cord compression requiring urgent specialist assessment.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Record respiratory rate, oxygen requirement, voice, stridor, ability to lie flat, facial and tongue oedema, consciousness and haemodynamics at intervals matching the severity of SVCO.
Repeat focused neurology in Pancoast disease, including hand power, sensation, reflexes, gait and sphincter symptoms when spinal or plexus extension is possible.
After SVC stenting, follow the interventional protocol for access-site bleeding, stent patency, recurrent swelling, chest pain and antithrombotic treatment.
During corticosteroid use, monitor glucose, mental state, infection and gastrointestinal risk, and document a stop or taper plan rather than allowing indefinite continuation.
Track pathology, molecular tests and staging investigations through a named lung-cancer team so urgent symptom relief does not fragment definitive diagnosis.
Revisit performance status, symptom burden, treatment goals and ceilings of care as results change the realistic balance between radical, palliative and supportive options.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Shoulder pain can be the lung symptom

Apical tumours may irritate parietal pleura and the lower plexus before causing cough. Persistent night pain, ulnar radiation or hand weakness should break an apparently orthopaedic frame.

Horner syndrome may be incomplete

The triad is not obligatory, and facial anhidrosis can be subtle. New unilateral ptosis with miosis and shoulder pain deserves thoracic-apex imaging even if ocular examination is otherwise reassuring.

Collaterals imply time, not safety

Prominent chest-wall veins suggest the obstruction developed sufficiently slowly for alternative channels to form; they do not exclude sudden deterioration from superimposed thrombosis or increasing tumour burden.

Stenting and anticancer therapy answer different problems

A stent restores venous flow rapidly but does not treat the cancer. Chemotherapy or radiotherapy may control the cause but may not act quickly enough for high-grade symptoms.

Biopsy strategy preserves future options

A poorly planned small sample can delay lymphoma classification or molecularly guided lung-cancer treatment. Imaging, pathology and procedural teams should agree the target and required material before sampling.

11Common pitfallsFrequent interpretation and management errors.

01
Treating all shoulder pain as musculoskeletal despite ulnar neurological symptoms, night pain or Horner signs.
02
Reassuring a patient after a chest radiograph that does not adequately show the lung apex.
03
Calling every SVCO a radiotherapy emergency without grading airway and cerebral compromise or establishing histology when time permits.
04
Starting dexamethasone before tissue sampling in a stable possible lymphoma without discussing the diagnostic consequence.
05
Anticoagulating pure external compression automatically, or overlooking superimposed catheter-related thrombus that genuinely needs treatment.
06
Sending an orthopnoeic patient flat for imaging without monitoring, airway support or a plan for deterioration.
07
Using oedematous upper-limb venous access unnecessarily and then misreading poor drug delivery or worsening swelling.
08
Allowing symptom relief after stenting to substitute for completing tissue diagnosis, staging and patient-centred cancer planning.